Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 123 results found. Search for [ COVID-19 vaccine Gamaleya ]

Results 60 to 80 of 123
BusinessToday.In
New Delhi, November 17, 2020
Moderna announced on Monday that its experimental COVID-19 vaccine 'mRNA-1273' was 94.5 per cent effective in preventing coronavirus. The statement was issued on the basis of interim data from a late-stage clinical trial. The announcement makes Moderna the second US-based pharmaceutical giant to have reported exceedingly hopeful results from clinical trials of their respective coronavirus vaccine candidates, after Pfizer vaccine. Watch the video for more.


BusinessToday.In
November 17, 2020
These early efficacy figures don't tell the whole story. The data results are based on a relatively smaller group of participants who received these vaccine shots. The actual efficacy could be known only after the final results are out as Phase 3 clinical trials end


BusinessToday.In
November 11, 2020
Russia coronavirus vaccine: The interim trial results were announced by Russia's sovereign wealth fund Russian Direct Investment Fund on Wednesday. RDIF is backing the vaccine and marketing it globally


BusinessToday.In
November 11, 2020
The major hurdle for the vaccine is storage and distribution. Pfizer's COVID-19 vaccine candidate needs to be stored at temperatures of minus 70 degrees Celsius (-94 F) or below


BusinessToday.In
November 10, 2020
Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology, was registered by the Russian Health Ministry


PTI
October 29, 2020
On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia


BusinessToday.In
October 29, 2020
Dr Reddy's and Russian Direct Investment Fund (RDIF) joined hands to carry out clinical trials and distribute 100 million doses of Sputnik V vaccine across India


BusinessToday.In
October 23, 2020
Dr Reddy's Laboratories has been given permission to conduct the trails of Russian COVID-19 vaccine Sputnik V, though, the date and time of the test will be determined by the company


BusinessToday.In
October 19, 2020
Presently, there are around 40 different coronavirus vaccines in various stages of human clinical trials, comprising one being developed by Oxford University and AstraZeneca, which is already in an advanced stage of testing


BusinessToday.In
October 18, 2020
Coronavirus vaccine: Meanwhile, the Drug Control General of India (DCGI) on Saturday approved Dr Reddy's proposal to conduct clinical trials for Sputnik V in India


Associated Press
October 15, 2020
We now need to increase production of the first vaccine and the second vaccine, Russian President Vladimir Putin said, adding that the priority was to supply the Russian market with the vaccines


BusinessToday.In
October 14, 2020
Dr Reddy's has teamed up with Russian Development Investment Fund (RDIF) to conduct trials and distribute 100 million doses of Sputnik V in India


Reuters
October 6, 2020
The Hyderabad-based pharmaceutical company had applied to the Drugs Controller General of India (DCGI) late last week, seeking permission to conduct phase-3 human clinical trials of the Russian vaccine


BusinessToday.In
October 1, 2020
Coronavirus vaccine update: In India, there are three COVID-19 vaccines under human trials--Bharat Biotech's COVAXIN, Oxford's COVDSHIELD, and Zydus Cadila's ZyCoV-D. Serum Institute has already begun a phase-3 trial of Oxford vaccine candidates at 17 sites


Reuters
September 29, 2020
Alexander Gintsburg, head of the Gamaleya Institute that produced the Sputnik V vaccine said that the pace of its development was necessary under the \"wartime\" conditions of a pandemic but no corners were being cut


BusinessToday.In
September 18, 2020
Kirill Dmitriev, CEO of Russia's sovereign wealth fund Russian Direct Investment Fund, says India will play a vital role in fighting Covid-19 and that government's Make in India initiative has made pharma sector stronger


BusinessToday.In
September 17, 2020
Dr Reddy's Laboratories stock which closed 4.24% higher in the previous session gained 4.21% or Rs 195 to close at Rs 4,826 on BSE today


Joe C Mathew
September 16, 2020
Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, a joint statement issued by RDIF and Dr Reddy's says


BusinessToday.In
September 16, 2020
Dr Reddy's Lab share touched an intraday high of Rs 4651.95, a rise of 4.7% on BSE


Chitranjan Kumar
September 16, 2020
The Sputnik V vaccine, developed by the Gamaleya research institute in coordination with the Russian defence ministry, is the world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform


PAGES 4 OF 7  12345